Please assess the completion status of the following clinical trial:

Trial Title: Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~In this study, included will be patients with corneal neovascularization secondary to various pathologies, including: Pterygium, Corneal chemical burn, S/P corneal transplantation, Herpetic keratitis, atopic keratoconjunctivitis, Chronic retinal detachment, Uveitis, panus secondary to blepharitis, S/P corneal foreign body.~Exclusion Criteria:~1. Patients with a history of retinal vein/artery occlusion or diabetes, currently treated with anti-VEGF or with a history of such treatment 3 months prior to enrollment.~2. Prior treatment for corneal neovascularization with the injection of Avastin/Lucentis.~3. Patients under 18~4. Pregnant women~5. Contra indications for Eylea treatment, including intraocular or periocular infection/inflammation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SC Aflibercept (Type: EXPERIMENTAL): The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization

Based on this trial design, predict the completion outcome and termination type (if applicable).